Combined Lentiviral and RNAi Technologies for the Delivery and Permanent Silencing of the hsp25 Gene

Methods in Molecular Biology

Volumn 787, Issue , 2011, Pages 121-136

  Kaur, Punit ^a,b   Nagaraja, Ganachari M ^a,b   Asea, Alexzander ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Gene silencing; Heat shock protein; Hsp25; Lentivirus; miRNA; RNAi; siRNA

Indexed keywords

HEAT SHOCK PROTEIN 27; HSPB1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ANIMAL; ARTICLE; CELL LINE; DRUG DELIVERY SYSTEM; GENE VECTOR; GENETIC PROCEDURES; GENETICS; LENTIVIRINAE; METABOLISM; MORTALITY; NEOPLASM; PROGNOSIS; RNA INTERFERENCE;

ANIMALS; CELL LINE; DRUG DELIVERY SYSTEMS; GENETIC TECHNIQUES; GENETIC VECTORS; HSP27 HEAT-SHOCK PROTEINS; LENTIVIRUS; NEOPLASMS; PROGNOSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

LENTIVIRUS;

EID: 80054764372     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-295-3_10     Document Type: Chapter

References (69)

1. Lindquist, S. (1986) The heat-shock response Annu Rev Biochem 55, 1151–91.
2. Hightower, L. E. (1991) Heat shock, stress proteins, chaperones, and proteotoxicity Cell 66, 191–7.
3. Ciocca, D. R., Adams, D. J., Edwards, D. P., Bjercke, R. J., and McGuire, W. L. (1983) Distribution of an estrogen-induced protein with a molecular weight of 24,000 in normal and malignant human tissues and cells Cancer Res 43, 1204–10.
4. Ciocca, D. R., Adams, D. J., Edwards, D. P., Bjercke, R. J., and McGuire, W. L. (1984) Estrogen-induced 24K protein in MCF-7 breast cancer cells is localized in granules Breast Cancer Res Treat 4, 261–8.
5. Ciocca, D. R., Asch, R. H., Adams, D. J., and McGuire, W. L. (1983) Evidence for modulation of a 24K protein in human endometrium during the menstrual cycle J Clin Endocrinol Metab 57, 496–9.
6. Adams, D. J., and McGuire, W. L. (1985) Quantitative enzyme-linked immunosorbent assay for the estrogen-regulated Mr 24,000 protein in human breast tumors: correlation with estrogen and progesterone receptors Cancer Res 45, 2445–9.
7. Horne, G. M., Angus, B., Wright, C., Needham, G., Nicholson, S., Harris, A. L., Innes, B., and Horne, C. H. (1988) Relationships between oestrogen receptor, epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer J Pathol 155, 143–50.
8. Ciocca, D. R., Stati, A. O., and Amprino de Castro, M. M. (1990) Colocalization of estrogen and progesterone receptors with an estrogen-regulated heat shock protein in paraffin sections of human breast and endometrial cancer tissue Breast Cancer Res Treat 16, 243–51.
9. Ciocca, D. R., Puy, L. A., Edwards, D. P., Adams, D. J., and McGuire, W. L. (1985) The presence of an estrogen-regulated protein detected by monoclonal antibody in abnormal human endometrium J Clin Endocrinol Metab 60, 137–43.
10. Langdon, S. P., Rabiasz, G. J., Hirst, G. L., King, R. J., Hawkins, R. A., Smyth, J. F., and Miller, W. R. (1995) Expression of the heat shock protein HSP27 in human ovarian cancer Clin Cancer Res 1, 1603–9.
11. Ciocca, D. R., Jorge, A. D., Jorge, O., Milutin, C., Hosokawa, R., Diaz Lestren, M., Muzzio, E., Schulkin, S., and Schirbu, R. (1991) Estrogen receptors, progesterone receptors and heat-shock 27-kD protein in liver biopsy specimens from patients with hepatitis B virus infection Hepatology 13, 838–44.
12. Malusecka, E., Zborek, A., Krzyzowska-Gruca, S., and Krawczyk, Z. (2001) Expression of heat shock proteins HSP70 and HSP27 in primary non-small cell lung carcinomas. An immunohistochemical study Anticancer Res 21, 1015–21.
13. Raymond, E., Faivre, S., and Armand, J. P. (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy Drugs 60 Suppl 1, 15–23; discussion 41–2.
14. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overex-presses HER2 N Engl J Med 344, 783–92.
15. Aslakson, C. J., and Miller, F. R. (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor Cancer Res 52, 1399–405.
16. Bausero, M. A., Bharti, A., Page, D. T., Perez, K. D., Eng, J. W., Ordonez, S. L., Asea, E. E., Jantschitsch, C., Kindas-Muegge, I., Ciocca, D., and Asea, A. (2006) Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell Tumour Biol 27, 17–26.
17. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells Nature 411, 494–8.
18. Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature 391, 806–11.
19. Caplen, N. J., Parrish, S., Imani, F., Fire, A., and Morgan, R. A. (2001) Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems Proc Natl Acad Sci USA 98, 9742–7.
20. Kuttenkeuler, D., and Boutros, M. (2004) Genome-wide RNAi as a route to gene function in Drosophila Brief Funct Genomic Proteomic 3, 168–76.
21. Croce, C. M. (2009) Causes and consequences of microRNA dysregulation in cancer Nat Rev Genet 10, 704–14.
22. Negrini, M., Nicoloso, M. S., and Calin, G. A. (2009) MicroRNAs and cancer--new paradigms in molecular oncology Curr Opin Cell Biol 21, 470–9.
23. Shah, P. P., Hutchinson, L. E., and Kakar, S. S. (2009) Emerging role of microRNAs in diagnosis and treatment of various diseases including ovarian cancer J Ovarian Res 2, 11.
24. Carpenter, A. E., and Sabatini, D. M. (2004) Systematic genome-wide screens of gene function Nat Rev Genet 5, 11–22.
25. Chi, J. T., Chang, H. Y., Wang, N. N., Chang, D. S., Dunphy, N., and Brown, P. O. (2003) Genomewide view of gene silencing by small interfering RNAs Proc Natl Acad Sci USA 100, 6343–6.
26. Shah, R. G., Ghodgaonkar, M. M., Affar el, B., and Shah, G. M. (2005) DNA vector-based RNAi approach for stable depletion of poly(ADP-ribose) polymerase-1 Biochem Biophys Res Commun 331, 167–74.
27. Zimmermann, T. S., Lee, A. C., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Rohl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H. P., and MacLachlan, I. (2006) RNAi-mediated gene silencing in non-human primates Nature 441, 111–4.
28. Wiznerowicz, M., and Trono, D. (2005) Harnessing HIV for therapy, basic research and biotechnology Trends Biotechnol 23, 42–7.
29. Zwierska, I., Walker, R. D., Choksy, S. A., Male, J. S., Pockley, A. G., and Saxton, J. M. (2006) Relative tolerance to upper-and lower-limb aerobic exercise in patients with peripheral arterial disease European Journal of Vascular and Endovascular Surgery 31, 157–63.
30. Wiznerowicz, M., and Trono, D. (2003) Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference J Virol 77, 8957–61.
31. Rubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Ihrig, M. M., McManus, M. T., Gertler, F. B., Scott, M. L., and Van Parijs, L. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference Nat Genet 33, 401–6.
32. Abbas-Terki, T., Blanco-Bose, W., Deglon, N., Pralong, W., and Aebischer, P. (2002) Lentiviral-mediated RNA interference Hum Gene Ther 13, 2197–201.
33. Gupta, S., Schoer, R. A., Egan, J. E., Hannon, G. J., and Mittal, V. (2004) Inducible, reversible, and stable RNA interference in mammalian cells Proc Natl Acad Sci USA 101, 1927–32.
34. Lo Bianco, C., Ridet, J. L., Schneider, B. L., Deglon, N., and Aebischer, P. (2002) alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson’s disease Proc Natl Acad Sci USA 99, 10813–8.
35. Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., and Trono, D. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector Science 272, 263–7.
36. Lu, X., Yu, Q., Binder, G. K., Chen, Z., Slepushkina, T., Rossi, J., and Dropulic, B. (2004) Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance J Virol 78, 7079–88.
37. Li, L., Lin, X., Staver, M., Shoemaker, A., Semizarov, D., Fesik, S. W., and Shen, Y. (2005) Evaluating hypoxia-inducible factor-1-alpha as a cancer therapeutic target via inducible RNA interference in vivo Cancer Res 65, 7249–58.
38. + T cell-mediated memory and tumor killing. Cancer Prevention Res (in press).
39. Amarzguioui, M., Rossi, J. J., and Kim, D. (2005) Approaches for chemically synthesized siRNA and vector-mediated RNAi FEBS Lett 579, 5974–81.
40. Judge, A., and MacLachlan, I. (2008) Overcoming the innate immune response to small interfering RNA Hum Gene Ther 19, 111–24.
41. Kehoe, J. W., and Kay, B. K. (2005) Filamentous phage display in the new millennium Chem Rev 105, 4056–72.
42. Monaci, P., Urbanelli, L., and Fontana, L. (2001) Phage as gene delivery vectors Curr Opin Mol Ther 3, 159–69.
43. van Nimwegen, M. J., and van de Water, B. (2007) Focal adhesion kinase: a potential target in cancer therapy Biochem Pharmacol 73, 597–609.
44. Lachmann, R. (2004) Herpes simplex virus-based vectors Int J Exp Pathol 85, 177–90.
45. Wade-Martins, R., Smith, E. R., Tyminski, E., Chiocca, E. A., and Saeki, Y. (2001) An infectious transfer and expression system for genomic DNA loci in human and mouse cells Nat Biotechnol 19, 1067–70.
46. Pelkmans, L., Kartenbeck, J., and Helenius, A. (2001) Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER Nat Cell Biol 3, 473–83.
47. Mukherjee, S., Abd-El-Latif, M., Bronstein, M., Ben-nun-Shaul, O., Kler, S., and Oppenheim, A. (2007) High cooperativity of the SV40 major capsid protein VP1 in virus assembly PLoS One 2, e765.
48. Sikorski, R., and Peters, R. (1998) Gene therapy. Treating with HIV Science 282, 1438.
49. Amado, R. G., and Chen, I. S. (1999) Lentiviral vectors – the promise of gene therapy within reach? Science 285, 674–6.
50. Sinn, P. L., Sauter, S. L., and McCray, P. B., Jr. (2005) Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors – design, biosafety, and production Gene Ther 12, 1089–98.
51. Larson, S. D., Jackson, L. N., Chen, L. A., Rychahou, P. G., and Evers, B. M. (2007) Effectiveness of siRNA uptake in target tissues by various delivery methods Surgery 142, 262–9.
52. Wolff, J. A., and Rozema, D. B. (2008) Breaking the bonds: non-viral vectors become chemically dynamic Mol Ther 16, 8–15.
53. Avnir, Y., Ulmansky, R., Wasserman, V., Even-Chen, S., Broyer, M., Barenholz, Y., and Naparstek, Y. (2008) Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis Arthritis Rheum 58, 119–29.
54. Lu, J. J., Langer, R., and Chen, J. (2009) A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery Mol Pharm 6, 763–71.
55. Akinc, A., Thomas, M., Klibanov, A. M., and Langer, R. (2005) Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis J Gene Med 7, 657–63.
56. Simoes, S., Moreira, J. N., Fonseca, C., Duzgunes, N., and de Lima, M. C. (2004) On the formulation of pH-sensitive liposomes with long circulation times Adv Drug Deliv Rev 56, 947–65.
57. Bradley, S. P., Rastellini, C., da Costa, M. A., Kowalik, T. F., Bloomenthal, A. B., Brown, M., Cicalese, L., Basadonna, G. P., and Uknis, M. E. (2005) Gene silencing in the endocrine pancreas mediated by short-interfering RNA Pancreas 31, 373–9.
58. Peer, D., Park, E. J., Morishita, Y., Carman, C. V., and Shimaoka, M. (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target Science 319, 627–30.
59. Yagi, N., Manabe, I., Tottori, T., Ishihara, A., Ogata, F., Kim, J. H., Nishimura, S., Fujiu, K., Oishi, Y., Itaka, K., Kato, Y., Yamauchi, M., and Nagai, R. (2009) A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth in vivo Cancer Res 69, 6531–8.
60. Bouxsein, N. F., McAllister, C. S., Ewert, K. K., Samuel, C. E., and Safinya, C. R. (2007) Structure and gene silencing activities of mon-ovalent and pentavalent cationic lipid vectors complexed with siRNA Biochemistry 46, 4785–92.
61. Liu, Y., Liggitt, D., Zhong, W., Tu, G., Gaensler, K., and Debs, R. (1995) Cationic liposome-mediated intravenous gene delivery J Biol Chem 270, 24864–70.
62. Lee, R. J., and Huang, L. (1996) Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer J Biol Chem 271, 8481–7.
63. Srinivas, G., Discher, D. E., and Klein, M. L. (2005) Key roles for chain flexibility in block copolymer membranes that contain pores or make tubes Nano Lett 5, 2343–9.
64. Woodrow, K. A., Cu, Y., Booth, C. J., Saucier-Sawyer, J. K., Wood, M. J., and Saltzman, W. M. (2009) Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA Nat Mater 8, 526–33.
65. Rozema, D. B., Lewis, D. L., Wakefield, D. H., Wong, S. C., Klein, J. J., Roesch, P. L., Bertin, S. L., Reppen, T. W., Chu, Q., Blokhin, A. V., Hags-trom, J. E., and Wolff, J. A. (2007) Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes Proc Natl Acad Sci USA 104, 12982–7.
66. Heidel, J. D., Yu, Z., Liu, J. Y., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., and Davis, M. E. (2007) Administration in nonhuman primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA Proc Natl Acad Sci USA 104, 5715–21.
67. Pirollo, K. F., and Chang, E. H. (2008) Targeted delivery of small interfering RNA: approaching effective cancer therapies Cancer Res 68, 1247–50.
68. Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., Elbashir, S., Geick, A., Hadwiger, P., Harborth, J., John, M., Kesavan, V., Lavine, G., Pandey, R. K., Racie, T., Rajeev, K. G., Rohl, I., Toudjarska, I., Wang, G., Wuschko, S., Bumcrot, D., Koteliansky, V., Limmer, S., Manoharan, M., and Vornlocher, H. P. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siR-NAs Nature 432, 173–8.
69. Reischl, D., and Zimmer, A. (2009) Drug delivery of siRNA therapeutics: potentials and limits of nanosystems Nanomedicine 5, 8–20.